The implementation of a new two-invoice system at one of Hutchison China Meditech’s (HCM) joint ventures – Hutchison Sinopharm – explains why group revenues fell to $214m (£163m) last year. The joint venture has stopped recognising gross sales from specific third-party products, and declaring service fees instead, prompting a fall in sales at the commercial division, from $205m to $173m.
IC TIP:
Buy
at
4100p